Board of Directors

Andrew Weil, M.D., is a world-renowned leader and pioneer in the field of integrative medicine. Combining a Harvard education and a lifetime of practicing natural and preventive medicine, Dr. Weil is the founder and director of the Andrew Weil Center for Integrative Medicine at the University of Arizona in Tucson, where he also serves as a Clinical Professor of Medicine and Professor of Public Health as well as the Lovell-Jones Professor of Integrative Medicine. He is a best-selling author of 15 books on healthy living, including Mind Over Meds; Fast Food, Good Food; True Food; Spontaneous Happiness; and Healthy Aging. Oxford University Press is currently producing the Weil Integrative Medicine Library, a 16-volume series for clinicians in various medical specialties. Dr. Weil is the editorial director of drweil.com , the leading online resource for healthy living based on the philosophy of integrative medicine, and pens Dr. Andrew Weil’s Self Healing monthly newsletter and a column in Prevention magazine. Dr. Weil is the founder/Chairman of the Weil Foundation, the founder/co-Chairman of Healthy Lifestyle Brands, and a founder/partner of True Food Kitchen restaurants. In 2017, he joined Seabourn and The Onboard Spa by Steiner in their “Spa and Wellness with Dr. Andrew Weil” mindful-living program on its cruise ships.

Dr. Michael Ehlers has more than 20 years of experience in biopharmaceutical leadership and biomedical research. Currently CEO of Limelight Bio and CSO of Apple Tree Partners, Dr. Ehlers was previously Executive Vice President and Head of Research & Development at Biogen, one of the world’s oldest and largest biopharmaceutical companies. Prior to that, Dr. Ehlers was Senior Vice President of BioTherapeutics R&D and the Chief Scientific Officer for Neuroscience & Pain at Pfizer. He holds a BS in chemistry from the California Institute of Technology, and M.D. and Ph.D. degrees from the Johns Hopkins University School of Medicine.

Dr. Sidney H. Kennedy is Professor of Psychiatry at the University of Toronto, the Arthur Sommer Rotenberg Chair in Suicide and Depression Studies, and a Scientist at Li Ka Shing Knowledge Institute and Toronto Western Research Institute, Toronto, Canada. Dr. Kennedy is the lead investigator for a large depression biomarker initiative. He has published extensively on new drug evaluation, neuroimaging and neurostimulation therapies, personality factors in depression, antidepressant effects on sexual function and treatment guidelines for Major Depressive Disorder and Bipolar Disorder.Dr. Kennedy is the Immediate Past President of the International Society for Affective Disorders, former President of the Canadian College of Neuropsychopharmacology, and the founding chair of the Canadian Network for Mood and Anxiety Treatments (CANMAT). He has published more than 350 peer reviewed publications and 11 books on depression and related topics.

Dr. Hanlon is the founding Program Director for the University of Toronto Pain Medicine Residency. He is an Assistant Professor in the Department of Anesthesia and practices Anesthesia and Pain Medicine at St. Michael’s Hospital where he is Medical Director of the Chronic Pain Clinic. Dr. Hanlon is the founding Program Director for the University of Toronto Pain Medicine Residency. He is an Assistant Professor in the Department of Anesthesia and practices Anesthesia and Pain Medicine at St. Michael’s Hospital where he is Medical Director of the Chronic Pain Clinic.

Dr. Waisglass has been working in the Canadian medical cannabis industry, influencing physicians, researchers, and regulatory authorities, both domestically and abroad. In 2014 he became the seminal physician and medical director of Canadian Cannabis Clinics. Soon after Aurora Cannabis acquired CCC in 2016 he became their medical director. Prior to his service in the cannabis space he was a family doctor for almost 40 years.

Dr. Robert McMaster is a Forensic Psychiatrist with a diverse practice. He works at CAMH with patients who have severe and persistent mental health diagnoses. He is also the primary consulting psychiatrist to the Ontario Court of Justice on Finch Avenue, is actively involved in outreach psychiatry, and works within the field of addiction medicine. He completed his subspecialty training at the University of Toronto and is now a faculty member.

Sanjay Singhal is a Canadian Partner for 500 Startups Canada and the founder of Audiobooks.com. President of the Aquanta Group, A long-term inventor, entrepreneur, VC and angel investor. Sanjay assists startups and entrepreneurs achieve success by investing in them and using his own experiences to reduce risk and commonly made mistakes. Sanjay has an Undergraduate and Masters Degree in Electrical Engineering from the University of New Brunswick and the University of British Columbia as well as an MBA from Cornell University.

Executive Chairman of the KSS Group of Companies, and founder and former CEO of Kingsdale Advisors, Wes Hall has established himself as a preeminent leader in the Canadian business landscape. Canada’s leading newspaper, The Globe & Mail, has called him one of the nation’s “most influential powerbrokers” and Canadian Business magazine named him one of the “most powerful business people” in 2016. Wes has been the recipient of numerous awards and honors over the years, and currently serves as a director of SickKids Foundation, a board member of Pathways to Education and Toronto International Film Festival (TIFF), and was former Chairman of the Board of Difference Capital Financial.

Mr. Weinand is the former President, CEO and Chairman of the Board of Bayer Pharmaceuticals, AG and has 30 years of experience in senior executive roles with a number of pharmaceutical companies, including Sanofi, Otzuka and Pfizer. He has a demonstrated ability to recognize opportunity, create a vision and strategy, and mobilize organizations behind successful execution. Mr. Weinand has launched and marketed some of the industry’s most successful products, including Lipitor, Neurontin, Abilify, and Cipro.

Ms. Boudreau joins the Company’s Board of Directors after most recently serving as Chief Operating Officer for the Bill & Melinda Gates Medical Research Institute. Prior to that role, Ms. Boudreau served as CFO for biotech companies Proteostasis Therapeutics and FORMA Therapeutics. Previously, Ms. Boudreau spent 16 years at Novartis and Pfizer, serving in strategy and senior finance roles, including Global CFO, Oncology business unit, CFO US Corporate, VP Investor Relations, VP Finance, Customer Business Unit and Commercial Operations, and VP Finance Global R&D. She has contributed to successful product launches, driven sales growth and increased profitability, integrated mergers & acquisitions, and provided leadership across Finance, IT, HR, Strategic Sourcing, Facilities, and Innovation, Quality and Process improvement.